Abstract
Beneficial treatment has not been established for chronic sensory ataxic neuropathy associated with Sjögren's syndrome (CSAN-SS). We describe two patients with CSAN-SS who clinically improved in response to D-penicillamine treatment. Their neuropathic symptoms were lessened after D-penicillamine, and the results of electrophysiologic studies support the clinical improvement. D-Penicillamine can be considered a potentially beneficial agent in the treatment of CSAN-SS.
MeSH terms
-
Adult
-
Antirheumatic Agents / therapeutic use*
-
Ataxia / drug therapy*
-
Ataxia / etiology
-
Evoked Potentials, Somatosensory
-
Female
-
Humans
-
Median Nerve / physiopathology
-
Neural Conduction / drug effects*
-
Neural Conduction / physiology
-
Neurologic Examination
-
Penicillamine / therapeutic use*
-
Sjogren's Syndrome / drug therapy*
-
Sjogren's Syndrome / physiopathology*
-
Sural Nerve / physiopathology
-
Ulnar Nerve / physiopathology
Substances
-
Antirheumatic Agents
-
Penicillamine